RU2002118308A - Способы получения полиморфных модификаций кларитромицина - Google Patents
Способы получения полиморфных модификаций кларитромицинаInfo
- Publication number
- RU2002118308A RU2002118308A RU2002118308/15A RU2002118308A RU2002118308A RU 2002118308 A RU2002118308 A RU 2002118308A RU 2002118308/15 A RU2002118308/15 A RU 2002118308/15A RU 2002118308 A RU2002118308 A RU 2002118308A RU 2002118308 A RU2002118308 A RU 2002118308A
- Authority
- RU
- Russia
- Prior art keywords
- clarithromycin
- water
- suspending
- converting
- suspended
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Способ превращения полиморфной Формы I кларитромицина в полиморфную Форму II, включающий суспендирование твердого вещества, содержащего кларитромицин Формы I, в воде.
2. Способ превращения Формы I кларитромицина в Форму II, включающий суспендирование Формы I кларитромицина в воде.
3. Способ по п.2, отличающийся тем, что Форму I кларитромицина суспендируют в 2-25 мл воды на один грамм Формы I кларитромицина.
4. Способ по п.2, отличающийся тем, что Форму I кларитромицина суспендируют в 3-10 мл воды на один грамм Формы I кларитромицина.
5. Способ по п.2, отличающийся тем, что суспендирование проводят при комнатной температуре.
6. Способ по п.2, дополнительно включающий сушку Формы II кларитромицина, что является следствием суспендирования Формы I в воде.
7. Способ по п.6, отличающийся тем, что сушку проводят в вакууме.
8. Способ получения Формы II кларитромицина, включающий превращение эритромицина А в кларитромицин Формы I и суспендирование Формы I кларитромицина в воде с образованием Формы II кларитромицина.
9. Способ по п.8, отличающийся тем, что кларитромицин Формы I суспендируют в 2-25 мл воды на один грамм Формы I кларитромицина.
10. Способ по п.8, отличающийся тем, что Форму I кларитромицина суспендируют в 3-10 мл воды на один грамм Формы I кларитромицина.
11. Способ по п.8, отличающийся тем, что суспендирование проводят при комнатной температуре.
12. Способ по п.8, дополнительно включающий сушку Формы II кларитромицина, что является следствием суспендирования Формы I в воде.
13. Способ по п.12, отличающийся тем, что сушку проводят в вакууме.
14. Форма II кларитромицина, образованная суспендированием Формы I кларитромицина в воде.
15. Фармацевтическая композиция, включающая терапевтически эффективное количество Формы II кларитромицина, образованной суспендированием Формы I кларитромицина в воде, и, по крайней мере, один фармацевтически приемлемый носитель.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17547700P | 2000-01-11 | 2000-01-11 | |
US60/175477 | 2000-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002118308A true RU2002118308A (ru) | 2004-02-20 |
Family
ID=22640371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002118308/15A RU2002118308A (ru) | 2000-01-11 | 2000-12-15 | Способы получения полиморфных модификаций кларитромицина |
Country Status (22)
Country | Link |
---|---|
US (2) | US6624292B2 (ru) |
EP (1) | EP1280535B1 (ru) |
JP (1) | JP2003519661A (ru) |
KR (1) | KR20020071012A (ru) |
CN (1) | CN1450903A (ru) |
AT (1) | ATE288758T1 (ru) |
AU (2) | AU2001222619C1 (ru) |
BR (1) | BR0016992A (ru) |
CA (1) | CA2397092A1 (ru) |
DE (1) | DE60018119T2 (ru) |
DK (1) | DK1280535T3 (ru) |
ES (1) | ES2236023T3 (ru) |
HR (1) | HRP20020572A2 (ru) |
HU (1) | HUP0204252A3 (ru) |
IL (1) | IL150698A0 (ru) |
IS (1) | IS6463A (ru) |
PL (1) | PL356645A1 (ru) |
PT (1) | PT1280535E (ru) |
RU (1) | RU2002118308A (ru) |
SI (1) | SI1280535T1 (ru) |
WO (1) | WO2001051059A1 (ru) |
ZA (1) | ZA200205229B (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001044262A1 (en) * | 1999-12-16 | 2001-06-21 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs and novel polymorph iv |
CA2397092A1 (en) * | 2000-01-11 | 2001-07-19 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
WO2001064224A1 (en) * | 2000-02-29 | 2001-09-07 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
DE60138876D1 (de) * | 2000-03-28 | 2009-07-16 | Sandoz Ag | Geschmackmaskierte granulierte teilchen |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
SI1285659T1 (sl) * | 2001-08-13 | 2008-02-29 | Fond Salvatore Maugeri Clinica | Uporaba klaritromicinskih sestavkov za pripravo zdravila za zdravljenje deformirajocega artritisa |
EP1648418A4 (en) | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
AU2004258949B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
CA2533292C (en) | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
CA2535177A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
EP1653924A4 (en) | 2003-08-12 | 2009-09-09 | Middlebrook Pharmaceuticals In | ANTIBIOTICS, USE AND FORMULATION ASSOCIATED |
CA2535780A1 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
US8460710B2 (en) | 2003-09-15 | 2013-06-11 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
WO2005061524A2 (en) * | 2003-12-22 | 2005-07-07 | Ranbaxy Laboratories Limited | Process for the preparation of form ii clarithromycin |
JP2007517039A (ja) * | 2003-12-24 | 2007-06-28 | アドバンシス ファーマスーティカル コーポレイション | 変性放出製剤の吸収増強 |
JP4833862B2 (ja) * | 2004-01-28 | 2011-12-07 | サイトイミューン サイエンシズ インコーポレイテッド | 官能化コロイド金属組成物および方法 |
US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
US20070015719A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
WO2007064595A2 (en) * | 2005-11-29 | 2007-06-07 | Bausch & Lomb Incorporated | Fluocinolone acetonide drug substance polymorphic interconversion |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20120219625A1 (en) * | 2009-09-02 | 2012-08-30 | Bernard Charles Sherman | Clarithromycin extended-release tablet |
MX2021001169A (es) | 2013-11-15 | 2023-02-10 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2473525A1 (fr) | 1980-01-11 | 1981-07-17 | Roussel Uclaf | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
JPS60214796A (ja) | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシン類の製法 |
JPS61103890A (ja) | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシンa誘導体 |
US4670549A (en) | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
US4672056A (en) | 1985-11-12 | 1987-06-09 | Abbott Laboratories | Erythromycin A derivatives and method of use |
US4640910A (en) | 1985-11-12 | 1987-02-03 | Abbott Laboratories | Erythromycin A silylated compounds and method of use |
KR960000434B1 (ko) | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
GB8721165D0 (en) | 1987-09-09 | 1987-10-14 | Beecham Group Plc | Chemical compounds |
JP2751385B2 (ja) | 1988-05-19 | 1998-05-18 | 大正製薬株式会社 | エリスロマイシンaオキシム及びその塩の製造方法 |
US5440505A (en) * | 1994-01-21 | 1995-08-08 | Intel Corporation | Method and circuitry for storing discrete amounts of charge in a single memory element |
US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
US5756473A (en) | 1995-11-21 | 1998-05-26 | Abbott Laboratories | 6-O-methyl erythromycin D and process for making |
US5837829A (en) | 1996-04-02 | 1998-11-17 | Abbott Laboratories | 9-oximesilyl erythromycin a derivatives |
US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
US5808017A (en) | 1996-04-10 | 1998-09-15 | Abbott Laboratories | Process for preparing erythromycin A oxime |
US5844105A (en) * | 1996-07-29 | 1998-12-01 | Abbott Laboratories | Preparation of crystal form II of clarithromycin |
DK0915899T3 (da) * | 1996-07-29 | 2004-11-29 | Abbott Lab | Fremstilling af krystallinsk form II af clarithromycin |
US5858986A (en) | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
US5945405A (en) | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
US5864023A (en) | 1997-02-13 | 1999-01-26 | Abbott Laboratories | 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives |
US5852180A (en) | 1997-11-17 | 1998-12-22 | Abbott Laboratories | Chemical synthesis of 6-O-alkyl erythromycin A |
US5932710A (en) | 1997-12-01 | 1999-08-03 | Abbott Laboratories | Process for preparing 6-O-alkyl-9-oxime erythromycin B |
US5892008A (en) | 1997-12-16 | 1999-04-06 | Abbott Laboratories | Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives |
KR100377159B1 (ko) * | 1998-09-09 | 2003-08-19 | 한미약품공업 주식회사 | 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법 |
WO2001044262A1 (en) * | 1999-12-16 | 2001-06-21 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs and novel polymorph iv |
CA2397092A1 (en) * | 2000-01-11 | 2001-07-19 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs |
WO2001064224A1 (en) | 2000-02-29 | 2001-09-07 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
-
2000
- 2000-12-15 CA CA002397092A patent/CA2397092A1/en not_active Abandoned
- 2000-12-15 DE DE60018119T patent/DE60018119T2/de not_active Expired - Fee Related
- 2000-12-15 KR KR1020027008908A patent/KR20020071012A/ko not_active Application Discontinuation
- 2000-12-15 HU HU0204252A patent/HUP0204252A3/hu unknown
- 2000-12-15 PT PT00986367T patent/PT1280535E/pt unknown
- 2000-12-15 WO PCT/US2000/033844 patent/WO2001051059A1/en active Application Filing
- 2000-12-15 CN CN00819302A patent/CN1450903A/zh active Pending
- 2000-12-15 AU AU2001222619A patent/AU2001222619C1/en not_active Ceased
- 2000-12-15 JP JP2001551483A patent/JP2003519661A/ja not_active Withdrawn
- 2000-12-15 DK DK00986367T patent/DK1280535T3/da active
- 2000-12-15 PL PL00356645A patent/PL356645A1/xx not_active Application Discontinuation
- 2000-12-15 EP EP00986367A patent/EP1280535B1/en not_active Revoked
- 2000-12-15 AT AT00986367T patent/ATE288758T1/de not_active IP Right Cessation
- 2000-12-15 ES ES00986367T patent/ES2236023T3/es not_active Expired - Lifetime
- 2000-12-15 IL IL15069800A patent/IL150698A0/xx unknown
- 2000-12-15 RU RU2002118308/15A patent/RU2002118308A/ru unknown
- 2000-12-15 SI SI200030650T patent/SI1280535T1/xx unknown
- 2000-12-15 AU AU2261901A patent/AU2261901A/xx active Pending
- 2000-12-15 BR BR0016992-7A patent/BR0016992A/pt not_active Application Discontinuation
- 2000-12-15 US US09/736,446 patent/US6624292B2/en not_active Expired - Fee Related
-
2002
- 2002-06-28 ZA ZA200205229A patent/ZA200205229B/en unknown
- 2002-07-04 HR HR20020572A patent/HRP20020572A2/hr not_active Application Discontinuation
- 2002-07-09 IS IS6463A patent/IS6463A/is unknown
-
2003
- 2003-06-10 US US10/459,178 patent/US6987175B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT1280535E (pt) | 2005-04-29 |
IL150698A0 (en) | 2003-02-12 |
HUP0204252A3 (en) | 2003-04-28 |
BR0016992A (pt) | 2002-12-31 |
AU2261901A (en) | 2001-07-24 |
US20020028920A1 (en) | 2002-03-07 |
DK1280535T3 (da) | 2005-04-04 |
JP2003519661A (ja) | 2003-06-24 |
US20030216555A1 (en) | 2003-11-20 |
HUP0204252A2 (hu) | 2003-03-28 |
US6624292B2 (en) | 2003-09-23 |
IS6463A (is) | 2002-07-09 |
US6987175B2 (en) | 2006-01-17 |
AU2001222619B2 (en) | 2005-04-28 |
DE60018119T2 (de) | 2006-05-04 |
CN1450903A (zh) | 2003-10-22 |
DE60018119D1 (de) | 2005-03-17 |
EP1280535A1 (en) | 2003-02-05 |
EP1280535B1 (en) | 2005-02-09 |
HRP20020572A2 (en) | 2005-04-30 |
WO2001051059A1 (en) | 2001-07-19 |
PL356645A1 (en) | 2004-06-28 |
ZA200205229B (en) | 2003-06-30 |
ES2236023T3 (es) | 2005-07-16 |
EP1280535A4 (en) | 2003-02-05 |
AU2001222619B8 (en) | 2005-07-14 |
CA2397092A1 (en) | 2001-07-19 |
SI1280535T1 (ru) | 2005-08-31 |
ATE288758T1 (de) | 2005-02-15 |
KR20020071012A (ko) | 2002-09-11 |
AU2001222619C1 (en) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002118308A (ru) | Способы получения полиморфных модификаций кларитромицина | |
CA2121435A1 (en) | Aqueous pharmaceutical suspension and process for preparation thereof | |
HUP0204091A2 (hu) | Eljárások a clarithromycin polimorf módosulatainak előállítására és az új polimorf IV módosulat, és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
RU2001118035A (ru) | Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы | |
HU9201329D0 (en) | The use of sulphonamides for medical purpose and process for the production of new sulphonamides | |
MA27815A1 (fr) | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent. | |
GB0117095D0 (en) | "Process for the preparation of pure citalopram" | |
NO20006039L (no) | Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin | |
EP1676839A3 (fr) | Nouvelle forme cristalline bêta du sel de tert-butylamine du perindopril, son procédé de préparation et les compositions pharmaceutiques qui la contiennent | |
RU2002105504A (ru) | Твердый диспергирующий агент некристаллического цефуроксим-аксетила, способ его получения и композиция для его перорального введения | |
HUP9900958A1 (hu) | Új 2-fluor-3-de[(2,6-didezoxi-3-C-metil-3-O-metil-alfa-L-ribohexopiranozil)oxi]-6-O-metil-3-oxo-eritromicin-származékok, és előállításuk | |
CA2354880A1 (en) | Method for the preparation of citalopram | |
EP1797875A3 (en) | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them | |
EP0992509A3 (en) | Novel macrolide derivatives | |
CA2510949A1 (en) | Polymorph of ritonavir | |
EP0326386A3 (en) | Isoquinolinones | |
US5912235A (en) | 10, 13, 15-trioxatricyclo 9.2.1.1.9.6 !-pentadecan one derivatives, method for their production and pharmaceutical compositions containing them | |
NZ509561A (en) | Crystalline forms of osanetant | |
CA2195975A1 (en) | An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides | |
RU97120930A (ru) | Конъюгаты полимиксина | |
RU2001135828A (ru) | Промежуточные соединения для синтеза производных бензимидазола и способ их получения | |
RU2003129888A (ru) | Производные калопорозида, способ их получения и их применение | |
GB2232419B (en) | Process for selective preparation of n4-substituted 1,4-diamino-2-nitrobenzenes | |
RU2006117769A (ru) | Производные бенгамида, способ их получения и их применение для лечения раковых заболеваний | |
CA2330669A1 (en) | Improved method for preparing pharmaceutically valuable norbenzomorphane derivatives |